Belinostat

Drug Overview

Belinostat (brand name Beleodaq) is an FDA-approved histone deacetylase (HDAC) inhibitor used in oncology. It is marketed under the brand name Beleodaq and is administered intravenously.

Belinostat is indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) in adults. By inhibiting histone deacetylase enzymes, belinostat promotes accumulation of acetylated histones and proteins, leading to cell cycle arrest, differentiation, and apoptosis in malignant T cells.

Relevant Genes and Their Roles

This guideline focuses on the enzyme UGT1A1, a key phase II drug-metabolizing enzyme found primarily in the liver. UGT1A1 (UDP-glucuronosyltransferase 1A1) adds glucuronic acid to belinostat metabolites, facilitating their elimination in bile and urine.

Genetic variants in UGT1A1 can alter enzymatic activity. Reduced-function alleles decrease glucuronidation, leading to slower drug clearance and higher systemic exposure. Conversely, normal-function alleles maintain expected drug elimination rates.

Impact of Genetics on Drug Response

Patients with different UGT1A1 metabolizer phenotypes may experience differences in belinostat exposure, toxicity risk, and efficacy. Poor metabolizers show higher drug levels and increased adverse reactions, while normal and intermediate metabolizers generally follow standard pharmacokinetics. When genotype is unknown or indeterminate, no specific dosage adjustments are recommended beyond standard care.

Want to know what your genetics say about how you'll respond to Belinostat?

A Gene2Rx report reads your own DNA to show how it may affect your response to Belinostat and your other medications.

{# data-track routes these through the sitewide cta_click listener in base.html, which attaches page_type / drug_name / guide_slug from the server-resolved page context. This one file instruments the mid-article CTA on ~114 content pages. #} Find out today

Or see an example report first

Expected Clinical Effects of Genetic Variation

Normal Metabolizer

Effect on drug levels: Expected standard clearance and exposure
Clinical consequence: Typical efficacy and toxicity profile
Side effects: Standard adverse effect incidence (e.g., fatigue, nausea) and severity as per label

Intermediate Metabolizer

Effect on drug levels: Slightly reduced clearance; modestly increased exposure
Clinical consequence: Generally manageable toxicity with standard dosing
Side effects: Mild increase in common adverse effects (e.g., hematologic changes) at expected frequency

Poor Metabolizer

Effect on drug levels: Decreased clearance leading to higher systemic concentrations
Clinical consequence: Increased risk of severe toxicity
Side effects: Higher incidence of hematologic toxicity (neutropenia, thrombocytopenia); severity may be moderate to severe

Indeterminate/Not Available

Effect on drug levels: Unknown
Clinical consequence: No specific guidance; follow standard dosing with clinical monitoring
Side effects: Unknown; monitor for standard adverse effects

Dosing Guidelines

The following dosing guidelines are based on FDA recommendations and UGT1A1 genotype status.

UGT1A1 Dosing Guidelines

Phenotype	Clinical Consequence	Guideline Recommendation
Normal Metabolizer	Expected standard metabolism and clearance	Initiate therapy with recommended starting dose
Intermediate Metabolizer	Near-normal metabolism with slight exposure increase	Initiate therapy with recommended starting dose
Poor Metabolizer	Higher systemic concentrations and higher adverse reaction risk	Reduce starting dose to 750 mg/m²
Indeterminate	Unknown impact	Initiate therapy with recommended starting dose
Not available	Unknown impact	Initiate therapy with recommended starting dose

Alternative Treatment Options

No specific alternate drugs or dosing strategies are included in the current FDA guideline. Clinicians may consider other HDAC inhibitors (e.g., vorinostat, panobinostat) based on patient profile and clinical context.

Sources and References

FDA – Table of Pharmacogenetic Associations

Genes that affect Belinostat

See the full list of drugs affected by each gene:

UGT1A1

UDP Glucuronosyltransferase Family 1 Member A1

Brand names containing Belinostat

See how your genetics affect each product Belinostat shows up in:

Beleodaq

Brand of belinostat

Disclaimer: This document is for informational purposes only and is not a substitute for medical advice. Clinical decisions should be made by a qualified healthcare professional.

Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.

I'm Interested